Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Positive results with respect to the presence of latent tuberculosis infection in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus testing compared with the use of QuantiFERON-TB Gold In-Tube testing.
Receiving appropriate antibiotic therapy in a timely manner is important, but clinicians must also consider potential antibiotic resistance in the hospital and surrounding community.
Researchers reported a case of drug resistance against 2 recently approved antitubercular medications: delamanid and bedaquiline.
For prevention of TB in people with HIV, a single month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone.
Number of tuberculosis cases and incidence decreased globally, but more progress is needed to meet targets.
The new interferon-gamma release assay QuantiFERON-TB Gold Plus had good sensitivity in children with pulmonary tuberculosis.
The first-ever UN High-Level Meeting on tuberculosis, in September 2018, resolved that ending the disease is a global priority.
Replacing ethambutol with moxifloxacin has not shown efficacy in tuberculosis treatment success in an 8-week trial.
A short regimen for rifapin-resistant tuberculosis was noninferior to 20-month regimen.
